Abstract
B-cell stimulatory factor-1 (BSF-1) is a T-cell product of relative molecular mass 20,000 (Mr 20K) initially described as a cofactor required for DNA synthesis by resting mouse B cells stimulated with low concentrations of anti-IgM antibodies1. It acts on resting B cells to enhance the expression of class II major histocompatibility complex (MHC) molecules2,3, to prepare these cells to respond more promptly to subsequent stimuli, such as anti-IgM antibodies4,5, and causes the secretion of IgG1 and IgE by B cells stimulated with lipopolysaccharide (LPS)6–9. BSF-1 has been shown to stimulate T cell lines10, resting T cells11 and some mast cell lines10. Recently, the designation interleukin-4 (IL-4) has been suggested for BSF-1. We report here the existence of high-affinity cell-surface receptors specific for BSF-1 on both B and T lymphocytes, and on cells of several other haematopoietic lineages, including mast cell, macrophage and undifferentiated haematopoietic cell lines. Resting B and T lymphocytes express receptors, which increase in number upon activation of B cells with LPS or anti-IgM, and of T cells with concanavalin A. Cross-linking of 125I-labelled-BSF-l to its receptors creates a complex of Mr∼80,000.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Howard, M. et al. J. exp. Med. 155, 914–923 (1982).
Roehm, N. W. et al. J. exp. Med. 160, 679–694 (1984).
Noelle, R., Krammer, P. H., Ohara, J., Uhr, J. W. & Vitetta, E. S. Proc. natn. Acad. Sci. U.S.A. 81, 6149–6153 (1984).
Rabin, E. M., Ohara, J. & Paul, W. E. Proc. natn. Acad. Sci. U.S.A. 82, 2935–2939 (1985).
Oliver, K., Noelle, R. J., Uhr, J. W., Krammer, P. H. & Vitetta, E. S. Proc. natn. Acad. Sci. U.S.A. 82, 2465–2467 (1985).
Vitetta, E. S. et al. Immun. Rev. 78, 137–157 (1984).
Sideras, P., Bergstedt-Lindqvist, S. & Severinson, E. Eur. J. Immun. 15, 593–598 (1985).
Vitetta, E. S. et al. J. exp. Med. 162, 1726–1731 (1985).
Coffman, R. L. et al. J. Immun. 136, 4538–4541 (1986).
Mosmann, T. R., Bond, M. W., Coffman, R. L., Ohara, J. & Paul, W. E. Proc. natn. Acad. Sci. U.S.A. 83, 5654–5658 (1986).
Hu-Li, J. et al. J. exp. Med. 165, 157–172 (1987).
Ohara, J., Lahet, S., Inman, J. & Paul, W. E. J. Immun. 135, 2518–2523 (1985).
Grabstein, K. et al. J. exp. Med. 163, 1405–1414 (1986).
Noma, Y. et al. Nature 319, 640–646 (1986).
Lee, F. et al. Proc. natn. Acad. Sci. U.S.A. 83, 2061–2065 (1986).
Ohara, J. & Paul, W. E. Nature 315, 333–336 (1985).
Pierce, J. H. et al. Cell 41, 685–693 (1985).
Barsumian, E. L., McGivney, A., Basciano, L. & Siraganian, R. Cell. Immun. 90, 131–141 (1985).
Rabin, E. M., Mond, J. J., Ohara, J. & Paul, W. E. J. Immun. 137, 1573–1576 (1986).
Yakura, H., Kawabata, I., Shen, F. W. & Katagiri, M. Fedn Proc. 44, 1532 (1985).
Mishra, G. C. et al. J. Immun. 137, 1590–1598 (1986).
Polla, B. S. Proc. natn. Acad. Sci. U.S.A. 83, 4878–4882 (1986).
Hwang, J. & Menon, K. M. J. J. biol. Chem. 259, 1978–1985 (1984).
Kurzinger, K. et al. J. Immun. 127, 596–602 (1981).
Peschell, C. et al. Blood (submitted).
Robb, R. J., Munck, A. & Smith, K. A. J. exp. Med. 154, 1455–1474 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ohara, J., Paul, W. Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature 325, 537–540 (1987). https://doi.org/10.1038/325537a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/325537a0
This article is cited by
-
Influenza virus infection expands the breadth of antibody responses through IL-4 signalling in B cells
Nature Communications (2021)
-
Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond
BioDrugs (2018)
-
Tumor-related interleukins: old validated targets for new anti-cancer drug development
Molecular Cancer (2017)
-
The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling
Oncogenesis (2017)
-
Regulation of gene expression, growth, and cell survival by IL-4: Contribution of multiple signaling pathways
Cell Research (1998)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.